National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2017 (No. 1) (PB 4 of 2017) (Cth)

PB 4 of 2017

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2017 (No. 1)

National Health Act 1953

I, LOUISE CLARKE, First Assistant Secretary (Acting), Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated 17 JANUARY 2017

LOUISE CLARKE

First Assistant Secretary (Acting)

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________________

Amendment instrument – Pharmaceutical benefits – early supply

1          Name of Instrument

(1)      This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2017 (No. 1)

(2)This Instrument may also be cited as PB 4 of 2017.

2          Commencement

This Instrument commences on 1 February 2017.

3          Amendment of PB 120 of 2015

Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).

Schedule 1        Amendments

1. Schedule 1, after entry for Oestradiol with norethisterone in the form Transdermal patches containing 620 micrograms oestradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8

insert:

Olaparib Capsule 50 mg 20 448 5

1. Schedule 1

omit:

Ribavirin and peginterferon alfa‑2a	Pack containing 140 tablets ribavirin 200 mg and 4 pre‑filled syringes peginterferon alfa‑2a injection 180 micrograms	20	1	2
Ribavirin and peginterferon alfa‑2a	Pack containing 168 tablets ribavirin 200 mg and 4 pre‑filled syringes peginterferon alfa‑2a injection 180 micrograms	20	1	2

1. Schedule 1, entry for Ustekinumab

omit:

Ustekinumab Injection 45 mg in 0.5 mL 20 1 1